·¢²¼Ê±¼ä:2017-12-03 18:38:10 ÎÄÕÂÀ´Ô´:»¥ÁªÍø
΢²© ΢ÐÅ QQ¿Õ¼ä

Ï´ÄÔÉñҩɯÆÕ°®Ë¼ÔâÑÛ¿ÆÒ½ÉúÉùÌÖ£ºÒ»Äê¿ñÂô7.5ÒÚÔª(9)

¡¡¡¡²Î¿¼ÎÄÏ×£º

¡¡¡¡Olson R J£¬ Braga-Mele R£¬ Chen S H£¬ et al£® Cataract in the Adult Eye Preferred Practice Pattern®[J]£® Ophthalmology£¬ 2017£¬ 124£¨2£©£º P1-P119£®

¡¡¡¡ÕÔ¿°ÐË£¬ ÑîÅàÔö£¬ÑÛ¿Æѧ [M]£® 8 °æ£¬ ±±¾©£º ÈËÃñÎÀÉú³ö°æÉ磬 2013

¡¡¡¡ÊÀ½çÎÀÉú×éÖ¯£¨WHO£©ÊÓÁ¦Ë𺦺Íä֢ʵ¿ö±¨µÀ£¬http://www.who.int/mediacentre/factsheets/fs282/zh/

¡¡¡¡Öйú·ÀäÖÎäÍø http://www.moheyes.com/

¡¡¡¡Abdelkader H£¬ Alany R G£¬ Pierscionek B£® Age©\related cataract and drug therapy£º opportunities and challenges for topical antioxidant delivery to the lens[J]£® Journal of Pharmacy and Pharmacology£¬ 2015£¬ 67£¨4£©£º 537-550£®

¡¡¡¡Balfour J A£¬ Clissold S P£® Bendazac lysine[J]£® Drugs£¬ 1990£¬ 39£¨4£©£º 575-596£®

ÁíÒ»ÊÓ½Ç

»»Ò»»»